Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2013 | 7.44 Million USD | -93.7% |
| 2012 | 118.21 Million USD | -0.65% |
| 2011 | 118.99 Million USD | -9.43% |
| 2010 | 131.38 Million USD | -37.88% |
| 2009 | 211.51 Million USD | 26.11% |
| 2008 | 167.72 Million USD | -25.72% |
| 2007 | 225.79 Million USD | -9.68% |
| 2006 | 249.98 Million USD | 310.09% |
| 2005 | 60.96 Million USD | 119.85% |
| 2004 | 27.72 Million USD | 0.0% |
| 2002 | 36.9 Million USD | -43.01% |
| 2001 | 64.76 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2014 Q1 | 6.46 Million USD | -13.17% |
| 2014 Q2 | 5.38 Million USD | -16.7% |
| 2013 FY | 7.44 Million USD | -93.7% |
| 2013 Q1 | 66.71 Million USD | -43.56% |
| 2013 Q3 | 15.54 Million USD | -25.67% |
| 2013 Q4 | 7.44 Million USD | -52.12% |
| 2013 Q2 | 20.91 Million USD | -68.65% |
| 2012 Q3 | 132.74 Million USD | -7.79% |
| 2012 Q1 | 169.87 Million USD | 42.75% |
| 2012 FY | 118.21 Million USD | -0.65% |
| 2012 Q4 | 118.21 Million USD | -10.95% |
| 2012 Q2 | 143.96 Million USD | -15.25% |
| 2011 Q4 | 118.99 Million USD | -11.36% |
| 2011 Q3 | 134.24 Million USD | -5.05% |
| 2011 Q1 | 165.88 Million USD | 26.26% |
| 2011 FY | 118.99 Million USD | -9.43% |
| 2011 Q2 | 141.39 Million USD | -14.76% |
| 2010 Q1 | 189.98 Million USD | -10.18% |
| 2010 FY | 131.38 Million USD | -37.88% |
| 2010 Q4 | 131.38 Million USD | -16.57% |
| 2010 Q2 | 189.13 Million USD | -0.45% |
| 2010 Q3 | 157.47 Million USD | -16.74% |
| 2009 FY | 211.51 Million USD | 26.11% |
| 2009 Q1 | 192.41 Million USD | 14.73% |
| 2009 Q2 | 167.67 Million USD | -12.86% |
| 2009 Q3 | 144.93 Million USD | -13.57% |
| 2009 Q4 | 211.51 Million USD | 45.94% |
| 2008 Q4 | 167.72 Million USD | -11.21% |
| 2008 Q1 | 214.54 Million USD | -4.98% |
| 2008 FY | 167.72 Million USD | -25.72% |
| 2008 Q2 | 205.86 Million USD | -4.04% |
| 2008 Q3 | 188.89 Million USD | -8.24% |
| 2007 Q2 | 238.27 Million USD | -3.4% |
| 2007 Q4 | 225.79 Million USD | -1.42% |
| 2007 Q3 | 229.05 Million USD | -3.87% |
| 2007 Q1 | 246.67 Million USD | -1.33% |
| 2007 FY | 225.79 Million USD | -9.68% |
| 2006 Q2 | 177.46 Million USD | 123.23% |
| 2006 Q3 | 150.56 Million USD | -15.16% |
| 2006 Q4 | 249.98 Million USD | 66.04% |
| 2006 Q1 | 79.49 Million USD | 30.41% |
| 2006 FY | 249.98 Million USD | 310.09% |
| 2005 FY | 60.96 Million USD | 119.85% |
| 2005 Q4 | 60.96 Million USD | 0.0% |
| 2004 Q4 | 27.72 Million USD | 0.0% |
| 2004 FY | 27.72 Million USD | 0.0% |
| 2002 FY | 36.9 Million USD | -43.01% |
| 2001 FY | 64.76 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -322107.792% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -280.096% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 29.477% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1248.077% |
| Rebus Holdings, Inc. | 5000.00 USD | -148760.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.284% |
| Qrons Inc. | 420.00 USD | -1772042.857% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -865.816% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 73.365% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1448.828% |
| Skye Bioscience, Inc. | 11.94 Million USD | 37.665% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 80.84% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -3.092% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -9648.016% |
| SQZ Biotechnologies Company | 107.18 Million USD | 93.056% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -419.751% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -10185.359% |
| Mesoblast Limited | 667.9 Million USD | 98.886% |
| Marizyme, Inc. | 22.01 Million USD | 66.191% |
| Genus plc | 1.02 Billion USD | 99.277% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -447.943% |
| Pharming Group N.V. | 462.85 Million USD | 98.392% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -124.66% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1391.467% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1087.081% |
| ContraFect Corporation | 20.67 Million USD | 64.007% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1806.672% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1847.527% |
| IMV Inc. | 31.33 Million USD | 76.246% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -79.521% |
| MultiCell Technologies, Inc. | 126.22 USD | -5896746.775% |
| ONE Bio Corp. | 70.08 Million USD | 89.38% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -692.071% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.208% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1624.058% |
| Q BioMed Inc. | 3.51 Million USD | -111.719% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 78.842% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2748.701% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9982.77% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.332% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -413.72% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 75.202% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -171.016% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -982.64% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -185.918% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7095.337% |
| Alpha Cognition Inc. | 2.45 Million USD | -203.527% |
| HST Global, Inc. | 1526.00 USD | -487645.74% |
| CSL Limited | 38.02 Billion USD | 99.98% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -653.365% |
| Halberd Corporation | 10.13 Thousand USD | -73367.575% |
| Enzolytics Inc. | 361.7 Million USD | 97.942% |
| Agentix Corp. | 261.39 Thousand USD | -2747.448% |
| Resverlogix Corp. | 8.11 Million USD | 8.281% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -296.351% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.836% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 84.397% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1063.594% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -32571.963% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 16.83% |
| AVAX Technologies, Inc. | 7.37 Million USD | -0.893% |
| Zenith Capital Corp. | 7410.00 USD | -100345.344% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.78% |
| Ember Therapeutics, Inc. | 184.00 USD | -4045008.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2212.884% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2747.753% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -702.081% |
| Kadimastem Ltd | 2.3 Million USD | -223.036% |
| Helix BioMedix, Inc. | 3.02 Million USD | -146.043% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 85.877% |
| BioStem Technologies, Inc. | 14.56 Million USD | 48.882% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -12936.396% |
| LadRx Corporation | 2.3 Million USD | -222.503% |
| Cell Source, Inc. | 195.17 Thousand USD | -3713.579% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2004.82% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2004.82% |
| NovAccess Global Inc. | 62.24 Thousand USD | -11857.011% |
| Itoco Inc. | 1.4 Million USD | -431.616% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7680.926% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6921.698% |
| Mobile Lads Corp. | 52.00 USD | -14313361.538% |
| CytoDyn Inc. | 11.13 Million USD | 33.163% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5105.914% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -41527.517% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1830.885% |
| SYBLEU INC | 330.46 Thousand USD | -2152.26% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1717.929% |
| International Stem Cell Corporation | 5.39 Million USD | -38.089% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5307.664% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 50.386% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 55.106% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -9321.519% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -760.784% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 0.984% |
| Neutra Corp. | 2851.00 USD | -260966.293% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 77.032% |
| PureTech Health plc | 693.97 Million USD | 98.927% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 7.782% |
| IXICO plc | 15.84 Million USD | 53.023% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 10.13% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.796% |
| CSL Limited | 38.02 Billion USD | 99.98% |
| Cellectis S.A. | 333.99 Million USD | 97.772% |